The purpose of this study was to determine the levels of isoniazid and ethionamide resistance and to identify associated mutations in endemic multidrug-resistant (MDR) strains of Mycobacterium tuberculosis from the Lisbon metropolitan area, Portugal.
Introduction
Isoniazid is one of the most effective drugs for the treatment of tuberculosis (TB). Ethionamide is a second-line drug used in the treatment of multidrug-resistant (MDR) TB. Both compounds are pro-drugs that need activation by different enzymes but share common pathways, which can lead to cross-resistance. The majority of the mutations responsible for high-level isoniazid resistance in Mycobacterium tuberculosis are found in the katG gene. 1 The second most commonly found mutations are observed in the promoter of inhA.
1 These mutations increase InhA expression and confer low-level resistance to isoniazid (0.1 ,MIC,1.0 mg/L). 2 Mutations in the inhA promoter also confer resistance to ethionamide, whose activity against M. tuberculosis depends on activation by EthA. 3 In addition to inhA promoter mutations, decreased susceptibility to isoniazid and ethionamide is associated with mutations in the structural region of inhA that decrease the affinity to the drug-NAD adduct. 2 In Portugal, the incidence rate of TB is high and the prevalence of MDR-TB and extensively drug-resistant (XDR) TB in the Lisbon region is a cause of major concern. 4 More than 90% of these strains show high-level isoniazid resistance associated with the C215T inhA promoter mutation. This genotype was also related with the high prevalence of ethionamide resistance. 5 To address the apparent incomprehensiveness between the level of isoniazid and ethionamide resistance in these strains and their mutation profile, we analysed the level of resistance towards isoniazid and ethionamide and identified associated mutations in MDR-TB strains isolated during 2009 -11 at the Mycobacteriology Laboratory of the Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa.
Materials and methods

Strains
Seventeen clinical strains of M. tuberculosis were included in the study (see Table 1 ). The isolates were obtained from different patients with active TB from hospitals in the Lisbon region and correspond to all MDR-TB strains received in our laboratory during 2009-11 for identification and first-line susceptibility testing. The selection criterion for this study was only MDR strains. All isolates were identified using the AccuProbe MTBC test (GenProbe Inc., San Diego, CA, USA) according to the manufacturer's instructions. The M. tuberculosis reference strain H37Rv ATCC27294
T was included as the control.
Susceptibility testing
First-line susceptibility testing was carried out with the BACTEC TM MGIT TM 960 system (Becton Dickinson Diagnostic Systems, Sparks, MD, USA) for streptomycin, isoniazid, rifampicin, ethambutol and pyrazinamide, according to the manufacturer's instructions. Semi-quantitative drug susceptibility testing of isoniazid and ethionamide was conducted using the MGIT 960 system and EpiCenter V5.80A software equipped with the TB eXIST module (Becton Dickinson), as previously described.
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Detection of mutations associated with resistance Genomic DNA was extracted using the QIAamp DNA Mini Kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer's instructions. The most common mutations in the structural katG gene and in the inhA regulatory region were investigated using Genotype MTBDRplus (Hain Lifescience GmbH, Germany) according to the manufacturer's instructions. Nucleic acid analysis of the complete inhA, katG and ethA genes and an internal fragment of the ndh gene (nt 560-931) (for a list of the primers and conditions see Table S1 , available as Supplementary data at JAC Online) was performed by DNA sequencing.
Strain typing
Mycobacterial interspersed repetitive unit -variable number of tandem repeats (MIRU-VNTR) genotyping was performed by multiplex PCR amplification of 24 loci, as described by Supply et al. 8 The genotype of these strains was analysed using the MIRU-VNTRplus web application 9 and the SITVITWEB database 10 when relevant.
Results
The quantitative isoniazid resistance levels were determined for the 17 MDR-TB isolates and the results are summarized in Table 1 . All isolates display isoniazid resistance levels .1 mg/L. According to the Genotype MTBDRplus assay, 16 of the 17 strains contain a mutation the inhA promoter region (C215T); one strain (MTB12) has a mutation in the katG gene (S315T).
The entire katG gene was sequenced for a selected group of strains (MTB2, 4, 5, 9, 10 and 13 -17), but no mutation was found. The C215T mutation is described to confer crossresistance to ethionamide. All isolates show high-level ethionamide resistance (.25 mg/L) ( Table 1) . Sequencing of the inhA open reading frame (ORF) revealed that all strains in addition to the C215T mutation in the inhA promoter harbour point mutations in the inhA structural gene ( Table 1) . Nine of these isolates carry the S94A mutation. In the remaining seven isolates, we detected the I194T mutation. The single isolate with a mutation in katG, in addition carries a mutation previously described in ethA, S266R. 11 No mutation was found in the region of the ndh gene analysed.
Analysis of the 17 strains by MIRU-VNTR typing revealed that 16/17 strains represent two clusters, cluster Lisboa3 and cluster Q1 (Figure 1 ). These 16 strains can be assigned to the Latino-American-Mediterranean (LAM) genotype and the remaining 1 to the Beijing genotype. Cluster Lisboa3 comprised the nine strains with the C215T/S94A mutations and the seven strains with the C215T/I194T substitutions were clustered in Q1 ( Figure 1 ).
Discussion
In the present study, we determined the levels of resistance to isoniazid and ethionamide for all MDR-TB strains isolated from 2009 to 2011 in our laboratory and we searched for mutations in target genes associated with resistance to isoniazid and ethionamide. We found that 16 strains have cumulative mutations in the inhA gene: the C215T mutation in the regulatory region coupled with mutations in the structural region of the gene, leading to the S94A and I194T substitutions. The presence of the mutation C215T has been reported to confer low-level resistance to isoniazid and cross-resistance to ethionamide. 1 The mutations S94A 2 and I194T 12,13 have also been reported to cause isoniazid resistance and both were associated with lowlevel resistance to isoniazid. 11, 13 However, there are few reports on the combinations C215T/S94A 3,11 and C215T/I194T. 12 The double mutation C215T/S94A has been reported to confer lowlevel resistance, 11 while the C215T/I194T combination was identified in one isolate with high-level resistance to isoniazid. 12 All 16 strains with a double mutation studied in our work exhibit high-level resistance to both isoniazid and ethionamide. In an attempt to compare the level of resistance of these strains carrying double mutations with the resistance level of strains carrying only the C215T mutation, we searched for additional isoniazid-resistant strains in our laboratory isolated during the same period. This C215T mutation alone was found among non-MDR strains and was correlated with low-level resistance to isoniazid (data not shown).
MIRU-VNTR typing of the strains showed the presence of two main clusters, Lisboa3 and Q1, indicating that the dissemination of these strains is clonal. However, the mutational profile related to drug resistance indicates that the acquisition of drug resistance-associated mutations is non-clonal (data not shown), except for isoniazid and rifampicin. Thus, resistance to isoniazid has been transmitted clonally, as all strains share the same C215T mutation and the S94A/I194T mutations were acquired subsequent to the C215T mutation. Sixteen out of 17 Isoniazid and ethionamide high-level resistance in circulating MDR-TB strains strains were found to belong to the LAM genotype, previously shown to be the main genotype circulating in Portugal.
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Fenner et al. 15 recently proposed that the genetic background of a strain may influence the level of resistance to isoniazid conveyed by particular drug resistance-conferring mutations. Our results suggest that these two mutations, when combined with the C215T mutation, can act synergistically to confer highlevel resistance in this particular group of strains. All non-MDR strains evaluated during the period of this study, with low-level resistance to isoniazid, belong to the LAM genotype, with only one belonging to Lisboa3 (data not shown). The single strain with a KatG S315T alteration is positioned in a completely separate branch and comprises the only Beijing strain found. From this we conclude that strain MTB12 is a foreign strain imported into the Lisbon area, not being part of the endemic circulating MDR clones. Comparison of the 12 loci MIRU with the SITVITWEB showed that MTB12 possess the MIRU international type MIT83, which corresponds to a modern Beijing type. Given the high-level ethionamide resistance observed in our isolates, the inclusion of ethionamide in second-line treatment regimens will have no benefit and other therapeutic combinations must be considered. 16 Our data point to the need for rapid diagnostic methods for the detection of these strains and strong laboratory support to provide timely and accurate drug resistance information to guide the implementation of appropriate therapy. 4 While our study is limited by the size of the sample evaluated, the strains investigated account for 45% of all the MDR-TB strains isolated in Lisbon during this period. 17 -19 In conclusion, we report that the presence of a mutation in the inhA regulatory region together with a mutation in the inhA coding region is associated with high-level resistance to both isoniazid and ethionamide among the MDR-TB strains circulating in Lisbon. Furthermore, we demonstrate that MDR-TB cases in Lisbon continue to be caused by a closely related family of strains, identified several years ago as being associated with MDR/XDR-TB. 20 This mutational pattern also suggests the involvement of strain-specific factors that could be a feature of Portuguese MDR-TB strains with relevance for their appropriate treatment.
